2.95
price down icon4.84%   -0.15
after-market After Hours: 2.95
loading
Trevi Therapeutics Inc stock is traded at $2.95, with a volume of 70,183. It is down -4.84% in the last 24 hours and up +13.03% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$3.10
Open:
$3.1
24h Volume:
70,183
Relative Volume:
0.32
Market Cap:
$214.15M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-9.5161
EPS:
-0.31
Net Cash Flow:
$-31.85M
1W Performance:
-6.65%
1M Performance:
+13.03%
6M Performance:
-3.91%
1Y Performance:
+38.50%
1-Day Range:
Value
$2.93
$3.10
1-Week Range:
Value
$2.91
$3.20
52-Week Range:
Value
$0.97
$4.00

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name
Name
Trevi Therapeutics Inc
Name
Phone
203-304-2499
Name
Address
195 CHURCH STREET, NEW HAVEN, CT
Name
Employee
26
Name
Twitter
@TreviThera
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
TRVI's Discussions on Twitter

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-12-23 Initiated B. Riley Securities Buy
Nov-22-22 Initiated SVB Leerink Outperform
Jun-03-19 Initiated BMO Capital Markets Outperform
Jun-03-19 Initiated Needham Buy
Jun-03-19 Initiated SVB Leerink Outperform
Jun-03-19 Initiated Stifel Buy
View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

pulisher
Sep 06, 2024

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MSN

Sep 06, 2024
pulisher
Sep 06, 2024

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MarketBeat

Sep 06, 2024
pulisher
Sep 05, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $33,162.62 in Stock - MarketBeat

Sep 05, 2024
pulisher
Sep 04, 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - StockTitan

Sep 04, 2024
pulisher
Sep 02, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.80 Average Target Price from Analysts - Defense World

Sep 02, 2024
pulisher
Aug 30, 2024

Trevi Therapeutics shares rise on bullish analyst initiation By Investing.com - Investing.com Canada

Aug 30, 2024
pulisher
Aug 30, 2024

Raymond James initiates Trevi Therapeutics at Outperform, sees first-to-market opportunity for Haduvio - Investing.com Canada

Aug 30, 2024
pulisher
Aug 30, 2024

Trevi Therapeutics (NASDAQ:TRVI) Research Coverage Started at Raymond James - MarketBeat

Aug 30, 2024
pulisher
Aug 30, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Aug 30, 2024
pulisher
Aug 30, 2024

Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Raymond James - Defense World

Aug 30, 2024
pulisher
Aug 29, 2024

Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Director Sells 4,555 Shares of Stock - MarketBeat

Aug 29, 2024
pulisher
Aug 29, 2024

Trevi therapeutics director Meeker sells shares worth over $13,000 - Investing.com

Aug 29, 2024
pulisher
Aug 28, 2024

Trevi Therapeutics to Participate in September Investor and Medical Conferences - Morningstar

Aug 28, 2024
pulisher
Aug 28, 2024

Trevi Therapeutics to Participate in September Investor and Medical Conferences - StockTitan

Aug 28, 2024
pulisher
Aug 21, 2024

Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com India

Aug 21, 2024
pulisher
Aug 21, 2024

Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com

Aug 21, 2024
pulisher
Aug 21, 2024

Trevi Therapeutics executive sells shares worth over $48,000 By Investing.com - Investing.com UK

Aug 21, 2024
pulisher
Aug 20, 2024

Trevi Therapeutics (NASDAQ:TRVI) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. I - MarketBeat

Aug 20, 2024
pulisher
Aug 20, 2024

EF Hutton Acquisition Co. I Upgrades Trevi Therapeutics (NASDAQ:TRVI) to Strong-Buy - Defense World

Aug 20, 2024
pulisher
Aug 19, 2024

Trevi Therapeutics Provides Business Updates - GuruFocus.com

Aug 19, 2024
pulisher
Aug 19, 2024

EF Hutton initiates coverage on Trevi Therapeutics shares with Buy rating - Investing.com Canada

Aug 19, 2024
pulisher
Aug 19, 2024

Price T Rowe Associates Inc. MD Purchases Shares of 13,561 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Aug 19, 2024
pulisher
Aug 18, 2024

Thomas Sciascia Sells 18,660 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock - Defense World

Aug 18, 2024
pulisher
Aug 17, 2024

Trevi Therapeutics executive trades over $130k in company stock By Investing.com - Investing.com Australia

Aug 17, 2024
pulisher
Aug 16, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Insider Thomas Sciascia Sells 18,660 Shares - MarketBeat

Aug 16, 2024
pulisher
Aug 16, 2024

Trevi Therapeutics executive trades over $130k in company stock - Investing.com

Aug 16, 2024
pulisher
Aug 16, 2024

Trevi Therapeutics executive trades over $130k in company stock By Investing.com - Investing.com UK

Aug 16, 2024
pulisher
Aug 16, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Vanguard Group Inc. - Defense World

Aug 16, 2024
pulisher
Aug 16, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Expected to Earn Q3 2024 Earnings of ($0.09) Per Share - MarketBeat

Aug 16, 2024
pulisher
Aug 15, 2024

Trevi Therapeutics to Participate in Upcoming September Events - GuruFocus.com

Aug 15, 2024
pulisher
Aug 15, 2024

B. Riley Research Analysts Decrease Earnings Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Aug 15, 2024
pulisher
Aug 15, 2024

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Longview News-Journal

Aug 15, 2024
pulisher
Aug 14, 2024

Trevi Therapeutics Announces the Initiation of its Phase 2b CORA - GuruFocus.com

Aug 14, 2024
pulisher
Aug 13, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2024 Earnings Call Transcript - Insider Monkey

Aug 13, 2024
pulisher
Aug 12, 2024

Earnings call: Trevi Therapeutics reports progress in chronic cough trials By Investing.com - Investing.com Australia

Aug 12, 2024
pulisher
Aug 12, 2024

Earnings call: Trevi Therapeutics reports progress in chronic cough trials - Investing.com

Aug 12, 2024
pulisher
Aug 12, 2024

Earnings call: Trevi Therapeutics reports progress in chronic cough trials By Investing.com - Investing.com Canada

Aug 12, 2024
pulisher
Aug 11, 2024

Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript - Seeking Alpha

Aug 11, 2024
pulisher
Aug 09, 2024

Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 - Quantisnow

Aug 09, 2024
pulisher
Aug 08, 2024

TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024 - InvestorPlace

Aug 08, 2024
pulisher
Aug 08, 2024

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance - Manchestertimes

Aug 08, 2024
pulisher
Aug 08, 2024

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance - PR Newswire

Aug 08, 2024
pulisher
Aug 08, 2024

Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Aug 08, 2024
pulisher
Aug 07, 2024

Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering - Quantisnow

Aug 07, 2024
pulisher
Aug 07, 2024

Institutional investors in Trevi Therapeutics, Inc. (NASDAQ:TRVI) see US$40m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance

Aug 07, 2024
pulisher
Aug 07, 2024

TRVITrevi Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Aug 07, 2024
pulisher
Aug 02, 2024

Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Thursday - MarketBeat

Aug 02, 2024
pulisher
Aug 02, 2024

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 - Marketscreener.com

Aug 02, 2024
pulisher
Aug 01, 2024

Chronic Refractory Cough Pipeline 2024 | GSK, Trevi Therapeutics - openPR

Aug 01, 2024
pulisher
Aug 01, 2024

Work at The Globe - The Globe and Mail

Aug 01, 2024
pulisher
Aug 01, 2024

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 – Company AnnouncementFT.com - Financial Times

Aug 01, 2024

Trevi Therapeutics Inc Stock (TRVI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Trevi Therapeutics Inc Stock (TRVI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
GOOD JENNIFER L
President & CEO
Sep 04 '24
Option Exercise
1.43
10,981
15,703
224,294
GOOD JENNIFER L
President & CEO
Sep 03 '24
Option Exercise
1.43
3,863
5,524
217,176
GOOD JENNIFER L
President & CEO
Sep 05 '24
Sale
3.11
40,277
125,310
213,313
GOOD JENNIFER L
President & CEO
Sep 04 '24
Sale
3.02
10,981
33,205
213,313
GOOD JENNIFER L
President & CEO
Sep 03 '24
Sale
3.02
3,863
11,677
213,313
$84.08
price down icon 1.22%
$27.52
price down icon 0.61%
$191.32
price down icon 0.14%
$89.94
price down icon 0.23%
$72.89
price down icon 0.75%
$246.78
price down icon 1.87%
Cap:     |  Volume (24h):